Surat, May 12, 2022: Anupam Rasayan India Ltd. (BSE- 543275, NSE- ANURAS, ISIN: INE930P01018), one of India’s leading custom synthesis and specialty chemical player, has announced its financial results for the quarter and year ended March 31, 2022.
Financial Highlights for Quarter Ended March 31st, 2022:
- Revenues at ₹3,172 million in Q4FY22 as compared to ₹2,717 million in Q4FY21 – growth of 17% Y-o-Y.
- EBITDA (incl. other revenue) at ₹969 million in Q4FY22 as compared to ₹655 million in Q4FY21 – growth of 48% Y-o-Y.
- Profit After Tax at ₹461 million in Q4FY22 as compared to ₹221 million in Q4FY21 – growth of 108% Y-o-Y.
Financial Highlights for Twelve Months Ended March 31st, 2022:
- Revenues at ₹10,660 million in FY22 as compared to ₹8,109 million in FY21 – growth of 31% Y-o-Y.
- EBITDA (incl. other revenue) at ₹3,121 million in FY22 as compared to ₹2,202 million in FY21 – growth of 42% Y-o-Y.
- Profit After Tax at ₹1,522 million in FY22 as compared to ₹703 million in FY21 – growth of 116% Y-o-Y.
Anand Desai, Managing Director of Anupam Rasayan, commented, “I am pleased to announce that we have delivered a robust year registering a total revenue growth of 29%, mostly driven by a healthy volume ramp-up. With new LOIs getting signed and older ones getting converted into long-term contracts, the visibility for topline growth in the years to come becomes clearer.”
“Further, our foray into Fluorination chemistries, which will drive our next phase of growth has been strengthened by our successful acquisition of Tanfac’s 26% stake. By the means of this acquisition, we look forward to backward integrate our supply chains in this vertical and focus on production of high value -high margin molecules that have application in varied industries which will give us impetus to enhance our margin profile.”
